Table 2 Summary of trial outcome and tazarotene dose levels (mg day−1)
From: A phase 1 study of tazarotene in adults with advanced cancer
Patient status | Total | 1.4 | 2.1 | 2.8 | 4.2 | 8.4 | 16.8 | 25.2 | 33.6 |
|---|---|---|---|---|---|---|---|---|---|
Initial study (day 0–week 12) | |||||||||
Enrolled | 34 | 6 | 5 | 3 | 2 | 2 | 3 | 7 | 6 |
Completed | 19 | 6 | 3 | 1 | 1 | 0 | 1 | 3 | 4 |
Withdrawn | 15 | 0 | 2 | 2 | 1 | 2 | 2 | 4 | 2 |
Disease progression | 9 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 1 |
Adverse events | 4 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
Patient's request | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Investigator's opinion | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Continuation study (week 12 onwards) | 5 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 3a |
